For men diagnosed with low testosterone, traditional testosterone replacement therapy (TRT) suppresses the body's natural hormone production and halts sperm production. That trade-off is acceptable for many—but for men who want to preserve fertility or restart their own hormonal axis, enclomiphene offers a mechanistically distinct alternative. As the trans-isomer of clomiphene citrate, enclomiphene acts as a selective estrogen receptor modulator (SERM) that blocks negative feedback at the pituitary, prompting the body to produce more luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The result: endogenous testosterone rises without suppressing spermatogenesis.

This article explains how enclomiphene works, who benefits most, what the evidence shows, and when exogenous TRT remains the better option. All enclomiphene use in adult men is currently off-label and compounded—the FDA has not approved enclomiphene as a standalone agent. Repros Therapeutics' application for Androxal (enclomiphene citrate) was not approved.

Medical Disclaimer

The information in this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. ZYNDIO connects adults with licensed providers via telehealth; the providers—not ZYNDIO—make all clinical decisions. Compounded medications dispensed through ZYNDIO partners are not FDA-approved drug products. They are prepared by state-licensed compounding pharmacies pursuant to a valid prescription. Individual results vary. Side effects, drug interactions, and contraindications exist for every therapy discussed here.

What Enclomiphene Is and How It Differs From Clomiphene

Clomiphene citrate—the original compound approved by the FDA in 1967 for ovulation induction in women—is a racemic mixture of two stereoisomers: zuclomiphene (cis-isomer) and enclomiphene (trans-isomer). Zuclomiphene has a long half-life (weeks) and accumulates in tissue, producing persistent estrogenic effects that can worsen side effects. Enclomiphene has a half-life of roughly 10 hours and clears the body quickly, isolating the pure SERM activity clinicians want: estrogen receptor antagonism at the hypothalamus and pituitary.

By blocking estrogen receptors in the pituitary, enclomiphene prevents circulating estradiol from signaling "testosterone levels are adequate." The pituitary interprets this as low estrogen and low testosterone, releases more gonadotropin-releasing hormone (GnRH), and increases secretion of LH and FSH. LH stimulates Leydig cells in the testes to produce testosterone. FSH supports Sertoli cells and spermatogenesis.

This is fundamentally different from exogenous TRT, which delivers testosterone from an external source (injection, gel, patch) and suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. A 2013 review in Asian Journal of Andrology by Crosnoe and colleagues noted that exogenous testosterone consistently suppresses LH, FSH, and intratesticular testosterone—leading to azoospermia or severe oligospermia in most men within months.

The Mechanism: Blocking Estrogen Feedback to Restore Endogenous Testosterone

The HPG axis operates as a tightly regulated feedback loop. When testosterone and estradiol levels are adequate, they bind receptors in the hypothalamus and pituitary, suppressing GnRH and LH/FSH release. When those signals are blocked—as with a SERM—the pituitary perceives a hormone deficit and increases gonadotropin output.

Enclomiphene exploits this loop without introducing exogenous androgens. Because the body's own testes produce the testosterone, intratesticular testosterone remains high enough to support sperm production. A 2015 phase 2 trial published in The Journal of Clinical Endocrinology & Metabolism (PMID: 25599616) enrolled 172 men with secondary hypogonadism and treated them with enclomiphene 12.5mg or 25mg daily for 90 days. Mean total testosterone rose from baseline 248 ng/dL to 512 ng/dL (25mg group), and LH/FSH levels increased proportionally. Critically, sperm concentration and motility were preserved or improved in men with baseline values.

This preservation of fertility is the primary clinical advantage over exogenous TRT.

Evidence Base: What the Trials Show and Where Gaps Remain

Enclomiphene's use in men is supported by a small but consistent body of phase 2 and investigational data. The 2015 JCEM trial cited above reported dose-dependent testosterone increases, with the 25mg daily cohort showing sustained elevation over 90 days and no significant reduction in sperm parameters. A follow-up analysis presented at the 2016 American Urological Association annual meeting tracked men who continued enclomiphene for six months; testosterone levels remained stable, and no pattern of tachyphylaxis (loss of effect over time) emerged.

A 2020 retrospective study in Urology (PMID: 32088215) reviewed outcomes in 76 men treated with enclomiphene 12.5-25mg daily for hypogonadism at a single academic center. Mean total testosterone rose from 265 ng/dL to 495 ng/dL at three months. Eighty-two percent of men achieved total testosterone above 350 ng/dL. Side effects were minimal—occasional hot flashes and mood changes in fewer than 10% of participants.

Despite these results, the FDA did not approve Repros Therapeutics' New Drug Application for Androxal (enclomiphene 12.5mg and 25mg tablets). The agency requested additional cardiovascular safety data—a pattern seen with SERMs generally, given clomiphene's mixed track record in older studies. As of 2026, enclomiphene remains available only as a compounded medication prescribed off-label.

Who Is a Candidate for Enclomiphene

Enclomiphene is most appropriate for men with secondary (hypothalamic-pituitary) hypogonadism who want to preserve or restore fertility. Typical candidates include:

  • Men under 40 with low testosterone and low or low-normal LH/FSH, indicating pituitary suppression rather than primary testicular failure.
  • Men planning to conceive in the near term who cannot tolerate the fertility suppression caused by exogenous TRT.
  • Men with a history of TRT-induced azoospermia who wish to restart spermatogenesis.
  • Men who prefer to avoid injections or daily topical applications.

Enclomiphene is NOT appropriate for men with primary hypogonadism (high LH/FSH, indicating testicular failure). In that scenario, the testes cannot respond to increased gonadotropin stimulation, and exogenous testosterone is the only viable option.

Other exclusions: men with active liver disease (SERMs are metabolized hepatically), uncontrolled cardiovascular disease, or a history of thromboembolic events. As with any hormonal therapy, a licensed provider must assess individual risk factors, lab values, and treatment goals.

Lab Monitoring: What to Track and Why

Enclomiphene therapy requires the same rigorous lab monitoring as exogenous TRT. Baseline labs should include:

  • Total testosterone (morning draw, fasting)
  • Free testosterone (calculated or measured)
  • LH and FSH
  • Estradiol
  • Complete blood count (CBC) to monitor hematocrit
  • Comprehensive metabolic panel (CMP) to assess liver and kidney function
  • Lipid panel

Follow-up labs at 6-8 weeks, then every 3-6 months. The goal is total testosterone in the mid-normal range (450-650 ng/dL for most men), with LH and FSH rising appropriately. If LH/FSH do not increase, the diagnosis of secondary hypogonadism may be incorrect, or another process (obesity, sleep apnea, medication interaction) may be suppressing the axis.

Estradiol should be monitored but typically does not rise excessively on enclomiphene, unlike with exogenous testosterone (which aromatizes to estradiol). Some men experience mild estradiol elevation; if symptomatic (gynecomastia, mood changes), dose adjustment or temporary discontinuation is warranted.

Hematocrit elevation is less common with enclomiphene than with exogenous TRT, but regular CBC monitoring remains standard of care.

Typical Dosing and Administration

Most providers start enclomiphene at 12.5mg daily, taken orally. If labs at 6-8 weeks show insufficient testosterone response, the dose may be increased to 25mg daily. Higher doses have not been studied extensively and risk increased side effects without proportional benefit.

Enclomiphene is taken continuously, not cycled. Skipping doses or irregular administration disrupts the feedback loop and produces erratic hormone levels.

Side effects are generally mild and include hot flashes, mood lability, and occasional visual disturbances (a known SERM effect, more common with clomiphene due to zuclomiphene accumulation). If visual changes occur, enclomiphene should be discontinued immediately and an ophthalmologic evaluation arranged.

When Exogenous TRT Is Still the Better Option

Enclomiphene is not a universal replacement for TRT. Men with primary hypogonadism (testicular failure) will not respond—LH and FSH are already elevated, and the testes cannot produce more testosterone even with additional pituitary stimulation. Exogenous testosterone is the only option in that scenario.

Men who have completed childbearing and prioritize symptom relief, muscle gain, or body composition may prefer the pharmacokinetic stability of long-acting testosterone injections (cypionate, enanthate) or topical formulations. Exogenous TRT produces more predictable trough and peak levels and does not depend on endogenous pituitary function, which can be impaired by obesity, sleep apnea, chronic opioid use, or aging.

Some men trial enclomiphene and do not achieve adequate testosterone response despite dose titration and lifestyle optimization. In those cases, transitioning to exogenous TRT—with or without adjunctive human chorionic gonadotropin (hCG) to preserve testicular function—is medically appropriate.

The Telehealth Evaluation: What to Expect

If you are considering enclomiphene through ZYNDIO, the telehealth consultation will cover:

  • Symptom history: fatigue, libido changes, erectile dysfunction, mood, cognitive changes.
  • Medication and supplement review, including any prior TRT, SERMs, or performance-enhancing substances.
  • Fertility goals and timeline.
  • Lab review: the provider will assess total and free testosterone, LH, FSH, estradiol, and any prior hormone panels.
  • Cardiovascular and hepatic risk assessment.

If the provider determines enclomiphene is clinically appropriate, a prescription is sent to a licensed compounding pharmacy. If baseline labs are missing or outdated, the provider may order labs before prescribing. Enclomiphene requires ongoing monitoring; expect follow-up labs at 6-8 weeks and every 3-6 months thereafter.

FAQ

Is enclomiphene the same as Clomid?

No. Clomid (clomiphene citrate) is a 50/50 mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a long half-life and produces persistent estrogenic effects. Enclomiphene isolates the trans-isomer with pure SERM activity and a short half-life, reducing side effects and tissue accumulation.

Will enclomiphene raise my sperm count?

Enclomiphene preserves or improves sperm production in men with secondary hypogonadism by maintaining high intratesticular testosterone. The 2015 JCEM trial and 2020 Urology retrospective both reported stable or improved sperm parameters. Individual response varies; men with baseline azoospermia or severe oligospermia should have semen analysis repeated at 3-6 months.

Can I take enclomiphene if I'm already on TRT?

Not simultaneously. Exogenous testosterone suppresses LH and FSH; adding enclomiphene will not overcome that suppression. Men who wish to transition from TRT to enclomiphene typically discontinue exogenous testosterone, allow the HPG axis to recover (often with hCG support), then start enclomiphene once baseline labs confirm secondary hypogonadism.

Does enclomiphene require a prescription?

Yes. Enclomiphene is a prescription-only medication compounded by state-licensed pharmacies. It is not available over the counter and is not an FDA-approved drug product.

How long does it take to see results?

Most men report symptom improvement—better energy, libido, mood—within 4-6 weeks. Lab confirmation of testosterone elevation typically occurs at 6-8 weeks. Sperm parameter changes, if relevant, take 3-6 months to manifest due to the 74-day spermatogenic cycle.

When to Talk to Your Provider

Enclomiphene is not appropriate for self-directed use. A licensed provider must confirm the diagnosis of secondary hypogonadism, rule out contraindications, and monitor labs throughout treatment. If you experience visual changes, chest pain, severe mood disturbance, or other concerning symptoms, contact your provider immediately.

If enclomiphene does not produce adequate testosterone response after 3 months of dose-optimized therapy, discuss alternatives with your provider. Exogenous TRT, hCG monotherapy, or combination regimens may be more appropriate based on your labs, symptoms, and fertility goals.

Last reviewed: 2026-04-25 by ZYNDIO Clinical Editorial Team (PharmD-led)